

LINCOLN PHARMACEUTICALS LIMITED



Regd. Office: "LINCOLN HOUSE" Behind Satyam Complex, Science City Road, Sola, Ahmedabad - 380060.

CIN: L24230GJ1995PLC024288, Ph. No.: +91-79-6777 8000, Fax: +91-79-6777 8062

Website: www.lincolnpharma.com, E-Mail: info@lincolnpharma.com

PART-I

Statement of Consolidated and Standalone Unaudited Financial Results for the Quarter and Nine Months ended on 31-Dec-2016

(Rs. In Lacs)

		Consolidated						Standalone					
		Quarter Ended			Nine Month Ended		Year Ended	Quarter Ended			Nine Month Ended		Year Ended
Sr. No.	Particulars	31/12/2016	30/09/2016	31/12/2015	31/12/2016	31/12/2015	31/03/2016	31/12/2016	30/09/2016	31/12/2015	31/12/2016	31/12/2015	31/03/2016
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income from Operations												
(a)	Net Sales/Income from Operations (Net of excise duty)	7,029.46	7,426.68	10,451.79	23,372.41	26,891.16	38,889.78	6,281.15	6,982.03	7,937.04	20,874.26	21,266.60	29,955.86
(b)	Other Operating Income	325.41	339.47	344.12	1,017.45	1,008.83	1,861.29	315.66	329.62	332.24	988.10	955.00	1,754.32
	Total income from Operations (net)	7,354.87	7,766.15	10,795.91	24,389.86	27,899.99	40,751.07	6,596.81	7,311.65	8,269.28	21,862.36	22,221.60	31,710.18
2	Expenses												
(-)	Cost of Materials consumed	1,875.64	1,985.84	1,746.17	5,669.05	5,173.05	7,178.70	1,331.37	1,482.59	1,256.20	4,202.04	4,009.19	5,578.37
(b)	Purchase of stock-in-trade	2,510.16	2,026.02	6,094.63	7,162.81	13,862.67	21,010.98	2,635.26	2,415.12	4,506.77	7,142.22	10,534.41	15,225.87
(c)	Changes in inventories of finished goods,												
(6)	work-in-progress and stock-in-trade	-629.06	-458.98	-280.44	-442.66	-654.19	-444.55	-542.93	-415.58	-275.50	-314.15	-626.55	-438.89
	Employee benefits expense	1,080.72	1,233.42	759.14	3,572.67	2,059.08	3,527.01	1,020.60	1,143.34	707.32	3,308.13	1,906.41	3,317.34
	Depreciation and amortisation expense	146.00	128.22	130.50	412.33	355.19	483.97	104.00	86.22	88.50	286.33	229.19	318.83
(f)	Other expenses	1,338.11	1,525.58	1,159.54	3,989.17	3,825.18	4,692.21	1,257.49	1,450.97	1,020.62	3,785.86	3,437.64	4,149.22
	Total Expenses	6,321.57	6,440.10	9,609.54	20,363.37	24,620.98	36,448.32	5,805.79	6,162.66	7,303.91	18,410.43	19,490.29	28,150.74
3	Profit / (Loss) from operations before other income, finance costs												
	and exceptional items (1-2)	1,033.30	1,326.05	1,186.37	4,026.49	3,279.01	4,302.75	791.02	1,148.99	965.37	3,451.93	2,731.31	3,559.44
4	Other Income	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
5	Profit / (Loss) from ordinary activities before finance costs and												
	exceptional items (3 + 4)	1,033.30	1,326.05	1,186.37	4,026.49	3,279.01	4,302.75	791.02	1,148.99	965.37	3,451.93	2,731.31	3,559.44
6	Finance Costs	134.84	176.83	201.64	522.71	587.80	996.19	101.03	131.86	155.11	396.01	447.01	553.73
7	Profit / (Loss) from ordinary activities after finance costs but before												
	exceptional items (5 + 6)	898.46		984.73	3,503.78	2,691.21	3,306.56	689.99	1,017.13	810.26	3,055.92	2,284.30	3,005.71
8	Exceptional Items	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
9	Profit / (Loss) from ordinary activities before tax (7 + 8)	898.46		984.73	3,503.78	2,691.21	3,306.56	689.99	1,017.13	810.26	3,055.92	2,284.30	3,005.71
10	Tax expense	249.13	281.73	338.51	892.70	720.39	926.58	196.36	241.81	296.53	771.48	619.39	831.10
11	Net Profit / (Loss) from ordinary activities after tax (9 + 10)	649.33	867.49	646.22	2,611.08	1,970.82	2,379.98	493.63	775.32	513.73	2,284.44	1,664.91	2,174.61
12	Extraordinary items (net of tax expense)	0.00		0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		0.00
13	Net Profit / (Loss) for the period (11 + 12)	649.33	867.49	646.22	2,611.08	1,970.82	2,379.98	493.63	775.32	513.73	2,284.44	1,664.91	2,174.61
14	Share of Profit / (loss) of associates * Minority Interest	0.00 2.21	0.00 1.29	0.00	0.00 4.61	0.00 4.35	0.00	0.00	0.00	0.00	0.00		0.00
15	5 9 11 111		1.29	1.90	4.61	4.35	11.74	0.00	0.00	0.00	0.00	0.00	0.00
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15)*	647.12	866.20	(44.22	2 (0/ 47	1,966.47	22/024	402.72	775.32	513.73	2,284.44	1 / / 4 01	2,174.61
17	` '	2,000.00	1,631.08	644.32 1.631.08	2,606.47 2,000.00	1,631.08	2,368.24 1,631.08	493.63 2.000.00	1,631.08	1.631.08	2,000.00	1,664.91 1,631.08	1,631.08
17	Paid-up equity share capital of face value Rs.10/- each Reserve excluding Revaluation Reserves as per balance sheet of	2,000.00	1,031.08	1,031.08	2,000.00	1,031.08	1,031.08	2,000.00	1,031.08	1,031.08	2,000.00	1,031.08	1,031.08
18							11,589.75						11,481.83
	previous accounting year Earnings Per Share (before and after extraordinary items)						11,507.75						11,401.83
19 i & ii.	(of Rs. 10/- each) (not annualised): Basic	3.42	5.31	3.95	15.17	12.06	14.52	2.61	4.75	3.15	13.29	10.21	13.33
	Earnings Per Share (before and after extraordinary items)	3.42	5.31	3.93	13.17	12.00	14.52	2.01	4.75	3.13	13.29	10.21	13.33
	(of Rs. 10/- each) (not annualised): Diluted	3.42	5.03	3.88	15.17	11.86	14.16	2.61	4.50	3.10	13.29	10.04	13.01
	(or ns. 107 - cacif) (flot affilialiseu).	3.42	5.03	3.00	13.17	11.00	14.10	2.01	4.30	3.10	13.29	10.04	Contd

Contd...

Notes:

- 1 The above financial results were reivewed by the Audit Committee and thereafter approved by the Board of Directors of the Company at the meeting held on 9th February, 2017.
- 2 Figures for the previous periods/year are being regrouped wherever necessary.
- 3 Since the revenue from different segment is less than 10% of total revenue, segment wise results are not given.
- 4 Statutory Auditors has carried out limited review for the quarterly result for quarter ended 31st December, 2016
- 5 Consolidated results includes results of its subsidiaries .
- 6 During the quarter Company has converted 36,89,200 convertible warrants in to equal number of equity shares of Rs.10/- each on preferential basis at price 82/- per share(which includes premium of Rs.72/-per share) pursuant to the SEBI (ICDR) Regulation, 2009. The Company has received final trading approval for the said Equity Shares from both the Stock Exchanges (i.e. NSE Limited and BSE Limited).

7

The Company has received approval from Ahmedabad Stock Exchange for voluntary Delisting of its Equity Shares vide its Letter dated 23.11.2016. Accordingly the Equity Shares stands delisted from Ahmedabad Stock Exchange Limited.

FOR LINCOLN PHARMACEUTICALS LIMITED

Sd/-[MAHENDRA G. PATEL] MANAGING DIRECTOR [DIN: 00104706]

Date: 09/02/2017 Place: Ahmedabad